New Delhi: India's pharmaceutical industry is accelerating its shift from low-cost generics to high-value medicines, complex chemistry and advanced therapies, with manufacturers investing in domestic production of active pharmaceutical ingredients (APIs) to reduce import dependence and strengthen global competitiveness, industry experts said.
The shift is being driven by changing domestic healthcare requirements, rising demand for chronic disease therapies, expanding export opportunities and government incentives to boost manufacturing capabilities.
